WARNING

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close [x]

Follow Us

Chronic Heart Failure


This study talks about the positive effects that CoQ10 has on the heart.  The study mentions how CoQ10 helps even a failing heart pump blood more adequately!  Read the abstract below if you want all the technical data!  The red highlighted section summarizes the results.


Sander S, Coleman CI, Patel AA, Kluger J, White CM. The Impact of Coenzyme Q10 on Systolic Function in Patients with Chronic Heart Failure. J Card Fail. 2006;12:464-472.

Intracardiac levels of coenzyme Q10 have been shown to increase with the use of coenzyme Q10 supplementation in patients with severe heart failure. Several randomized studies have been conducted comparing the effects of coenzyme Q10 compared to placebo on systolic function and ventricular size. However, the results of these studies have been inconsistent. Due to the small nature of trials conducted to date and possible lack of power to demonstrate efficacy of coenzyme Q10, this meta-analysis was conducted. Eleven randomized, controlled trials published between 1996 and 2001, evaluating the use of coenzyme Q10 in heart failure were included. The primary outcome was ejection fraction. Secondary endpoints were cardiac output, cardiac index, stroke volume, and stroke index. The dose of coenzyme Q10 utilized ranged from 60 mg to 200 mg daily. The treatment periods ranged from 1 to 6 months. The results demonstrated a 3.7% net improvement in ejection fraction (85% CI 1.59-5.77), p<0.00001). In patients not receiving ACEI therapy, the effect on ejection fraction was more profound (6.74%, 95% CI 2.63-10.86). None of the secondary endpoints were found to be statistically significant. Based on these results, it appears that coenzyme Q10 supplementation can significantly improve ejection fraction. However, this benefit may be diminished in patients already receiving standard heart failure medications, such as ACEI. Larger, longer-term trials are needed to confirm these results. Additionally, studies evaluating the effect of coenzyme Q10 on different etiologies of heart failure are also necessary as some patients may respond better than others based on the type of heart failure present.



This study talks about how CoQ10 actually improves survival rate for those with chronic heart failure!  Below is an abstract of the study and the red highlighted section is a summary of the results.

 


Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10. An Independent Predictor of Mortality in Chronic Heart Failure. J Am Coll Cardiol. 2008;52:1435-1441.

A decreased level of myocardial coenzyme Q10 has been demonstrated in patients with heart failure. Additionally, the levels of coenzyme Q10 directly correlate to disease severity, with lower levels being associated with a worse functional class. However, no trials relating decreased levels of coenzyme Q10 in heart failure to outcomes have been conducted. Therefore, this cohort study sought to investigate this hypothesis by evaluating coenzyme Q10 levels in 236 patients admitted to the hospital for CHF. The primary endpoint was all-cause mortality. The majority of patients (65%) had NYHA class II with a median age of 77 years. The median ejection fraction was 37%. Patients were followed up at 3-month intervals and the median follow-up period was 2.69 years. Plasmacoenzyme Q10 levels were measured with high-performance liquid chromatography with electrochemical detection. Receiver operator characteristic (ROC) curves were used for mortality prediction. Kaplan-Meier cumulative survival curves were constructed from date of admission with dichotomous data obtained with the cut-point from the ROC curve. The Kaplan-Meier curves for coenzyme Q10, coenzyme Q10 to total cholesterol ratios, and the coenzyme Q10 to LDL-C ratio, showed a significant reduction in survival with lower coQ10 levels and CoQ10 to lipid ratios (p<0.01). These findings demonstrate that plasma coenzyme Q10 levels are an independent predictor of mortality and that long term deficiency may lead to a poorer prognosis. The event rate of this cohort was low; therefore, a large controlled intervention study is warranted.